Each tablet contains Betahistine mesilate 6 mg.
Pharmacology: BETRIS contains betahistine mesilate that dilates precapillary sphincters thus increasing the blood flow in the inner ear, thereby endolymphatic hydrops. It also improves cerebral circulation, increasing blood flow in the internal carotid artery.
Relief of vertigo, equilibrium disturbances and dizziness associated with Meniere's diseases (Meniere's syndrome) and Peripheral vertigo.
Usually for adults: Administer oral 1-2 tablets ( 6-12 mg ) three times a day after meals.
The dosage should be adjusted according to the age of patient and severity of symptoms.
In patients with known hypersensitivity to betahistine mesilate.
Careful administration in: 1. Patient with a history of peptic ulcer or with active digestive ulcer.
2. Patient with bronchial asthma.
3. Patient with pheochromocytoma.
Pregnant women: Safety of betahistine mesilate during pregnancy has not been reported. This drug should be administered to pregnant patients or women suspected of being pregnant, only if the expected therapeutic benefit is thought to outweigh any possible risk.
Adverse effects occur by treatment with betahistine mesilate are nausea, vomiting and hypersensitivity reactions such as skin rash.
Interaction between betahistine mesilate tablets and other drug has not been reported.
N07CA01 - betahistine ; Belongs to the class of antivertigo preparations.
Betris tab 6 mg
10 × 10's
Sign Out
